rAAV/Her-2/neu loading of dendritic cells for a potent cellular-mediated MHC class I restricted immune response against ovarian cancer

Viral Immunology

Volumn 21, Issue 4, 2008, Pages 435-442

  Yu, Yuefei ^a   Pilgrim, Petra ^a   Zhou, Wei ^a   Gagliano, Nicoletta ^a,b   Frezza, E Eldo ^a   Jenkins, Marjorie ^c   Weidanz, Jon A ^a,c   Lustgarten, Joseph ^d   Cannon, Martin ^e   Bumm, Klaus ^f   Cobos, Everardo ^a   Kast, W Martin ^g,h   Chiriva Internati, Maurizio ^a,h  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF MILAN   (Italy)

^c TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d MAYO GRADUATE SCHOOL   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h Kiromic Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PARVOVIRUS VECTOR; RECOMBINANT ADENO ASSOCIATED VIRUS; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BACTERIAL GENE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DISEASE COURSE; DRUG MECHANISM; DRUG POTENCY; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IN VITRO STUDY; LOW DRUG DOSE; MAJOR HISTOCOMPATIBILITY COMPLEX; OVARY CANCER; OVARY DEVELOPMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; SELF CONCEPT; STIMULATION; T LYMPHOCYTE; TARGET CELL; VIRAL GENE DELIVERY SYSTEM;

ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DEPENDOVIRUS; FEMALE; GENE EXPRESSION; GENES, MHC CLASS I; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; LEUKOCYTES, MONONUCLEAR; OVARIAN NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC;

ADENO-ASSOCIATED VIRUS;

EID: 58149263381     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/vim.2008.0029     Document Type: Article

References (36)

1. Brossart P, Wirths S, Stuhler G, Reichardt V, Kanz L, and Brugger W: Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;98:3102-3108.
2. Buhring H, Sures I, Jallal B, et al.: The receptor tyrosine kinase p185Her2 is expressed on a subset of B-lymphoid blasts from patients with acute lymphoblastic leukemia and chronic myelogenous leukemia. Blood 1995;86:1916-1923.
3. Chiriva-Internati M, Liu Y, Weidanz JA, et al.: Testing recombinant adeno-associated virus-gene loading of dendritic cell for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 2003;102:3100-3107.
4. Chiriva-Internati M, Liu Y, Salati E, et al.: Efficient generation of cytotoxic T lymphocytes against cervical cancer cells by adeno-associated virus/human papillomavirus type 16 E7 antigen gene transduction into dendritic cells. Eur J Immunol 2002;32:30-38.
5. Collaco RF, Cao X, and Trempe JP: A helper virus-free packaging system for recombinant adeno-associated virus vectors. Gene 1999;238:397-405.
6. Disis M, and Cheever M: HER-2/1 neu protein: a target for antigen specific immunotherapy of human cancer. Ads Cancer Res 1997;71:343-371.
7. Disis ML, Calenoff E, Mclaughlin G, et al.: Existent T cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 1994;54:16-20.
8. Disis ML, Shiota FM, and Cheever MA: Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for "self" tumour antigens. Immunology 1998;93:192-199.
9. Fisher-Adams G, Wong KK Jr, Podsakoff G, Forman SJ, and Chatterjee S: Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction. Blood 1996;88:492-504.
10. Fisk B, Blevins TL, Wharton JT, and Ioannides CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 1995;181:2109-2117.
11. Hermonat PL, and Muzyczka N: Use of adeno-associated virus as a mammalian DNA cloning vector: transduction of neomycin resistance into mammalian tissue culture cells. Proc Natl Acad Sci USA 1984;81:6466-6470.
12. Correa I, and Plunkett T: Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 2001;3:399-403.
13. Katsumata M, Okudaira T, Samanta A, et al.: Prevention of breast tumour development in vivo by downregulation of the pl85neu receptor. Nat Med 1995;1:644-648.
14. Kono K, Rongcun Y, Charo J, et al.: Experimental cancer identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes. Int J Cancer 1998;78:202-208.
15. Liu Y, Chiriva-Internati M, Grizzi F, et al.: Rapid induction of cytotoxic T-cell antigen gene delivery into human dendritic cells by an adeno-associated virus vector. Cancer Gene Therapy 2001;8:948-957.
16. Liu Y, Santin AD, Mane M, et al.: Transduction and utility of the granulocyte-macrophage colony stimulating factor gene into dendritic cells by adeno-associated virus. J Interferon Cytokine Res 2000;20:21-30.
17. Lustgarten J, Theobald M, Labadie C, et al.: Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol 1997;52:109-118.
18. Medeiros R, Pereira D, Afonso N, et al.: Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 2003;8:156-161.
19. Muller M, Grunebach F, Kayser K, et al.: Expression of Her-2/neu on acute lymphoblastic leukemias: Implications for the development of immunotherapeutic approaches. Clin Cancer Res 2003;10:3448-3453.
20. Okugawa T, Ikuta Y, Takahashu Y, et al.: A novel human HER2-derived peptide-A24 restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals. Eur J Immunol 2000;30:3338-3346.
21. Peoples GE, Goedegebuure PS, Andrews JVR, et al.: HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer. J Immunol 1993;151:5481-5491.
22. Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, and Medeiros R: The influence of HER-2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 2005;335:1173-1178.
23. Podsakoff G, Wong KK Jr, and Chatterjee S: Efficient gene transfer into nondividing cells by adeno-associated virus-based vectors. J Virol 1994;74:5656-5666.
24. Ponnazhagan S, Mahendra G, Curiel D, and Shaw D: Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo immunotherapy. J Virol 2001;10:9493-9501.
25. Romani N, Gruner S, Brang D, et al.: Proliferating dendritic cell progenitors in human blood. J Exp Med 1994;180:83-93.
26. Ross J, Fletcher J, Bloom K, et al.: Targeted therapy in breast cancer. Mol Cell Proteomics 2004;3:379-398.
27. Sallusto F, and Lanzavecchia A: Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med 1994;179:1109-1118.
28. Schlichtholz B, Legros Y, Gillet D, et al.: The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992;52:6380-6384.
29. Slamon DJ, Godolphin W, Jones LA, et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-711.
30. Spitz MR, Wu X, and Mills G: Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 2005;23:267-275.
31. Sun JY, Krouse RS, Forman SJ, et al.: Immunogenicity of a p210(BCR-ABL) fusion domain candidate DNA vaccine targeted to dendritic cells by a recombinant adeno-associated virus vector in vitro. Cancer Res 2002;62:3175-3183.
32. Takahashi M, Chen W, Byrd D, et al.: Antibody responses to ras proteins in patients with colon cancer. Clin Cancer Res 1995;1:1071-1077.
33. Veldwijk MR, Topaly J, Laufs S, et al.: Development and optimization of a real time quantitative PCR-based method for the titration of AAV-2 vector stocks. Mol Ther 2002;6:272-278.
34. Yoshino I, Peoples GE, Goedegebuure PS, Maziarz R, and Eberlein TJ: Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer. J Immunol 1994;152:2393-2400.
35. Young JW, and Inaba K: Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J Exp Med 1996;183:7-11.
36. Zhou SZ, Broxmeyer HE, Cooper S, Harrington MA, and Srivastava A: Adeno-associated virus 2-mediated gene transfer in murine hematopoietic progenitor cells. Exp Hematol 1993;21:928-933.